AIH2/26: Autoimmune Liver Diseases

This EQA round of the accredited programme was carried out according to the document ***EQA Plan 2026***.
Typing conventions: *We are using comma as a decimal separator and dates in day.month.year format.*

Samples

The samples were prepared by the subcontractor.
Sample A was a pooled serum of negative patient samples.
Sample B was a pooled serum of patient samples, expected to be positive for AMA and AMA-M2.

Assigned values

The assigned values are determined by the consensus of the participants. In the case of qualitative results, the consensus is reached if at least 80 % of the participants agree on the result.

Supervisor's comment

There were 66 participants in this round of which 2 from Austria and 12 from Slovakia.
Consensus was reached for all tests.
The participants' results were excellent, as the overall success rate for nearly all exams was 95% or higher.

A lower success rate (92 %) was observed only for the **AMA** test, where 4 participants reported an inconclusive result for sample B (these participants belonged to the most frequently represented reagent groups: 2 using Euroimmun and 2 using INOVA Diagnostics).

Educational note

AMA, anti-LKM and SMA tests can only be performed by indirect immunofluorescence. It is possible that some manufacturers also label ELISA and immunoblot kits as such, usually without specifying the target antigens used. In contrast, diagnostics against purified LKM1 antigens and mitochondrial M2 antigen is very difficult or impossible using commercial indirect immunofluorescence kits and these laboratory tests should be performed by ELISA, immunoblot or ALBIA.

Long-term success rate

You can find the overview of the total success of the participants of this round over last 2 years in the following table. Particular ranges of success are defined in the column headers (percentage of the tests on which the participant reported the correct result). Next 2 lines contain both absolute and relative number of participants who reached the success from the header**.**

Success		***0 %***	***1 - 74 %***	***75 - 79 %***	***80 - 89 %***	***90 - 94 %***	***95 - 99 %***	***100 %***
Success in words		unsatisfactory		acceptable	good	very good	excellent	
Count	absolute	0	0	0	2	4	7	53
	relative	-	-	-	3 %	6,1 %	11 %	80 %
Note: You can find your individual success over last 2 years in your result sheet.								

Overall success of most participants of this round over the last 2 years is 95 % or higher.
Success rates below 95 % should be considered to be an impulse to improve.

Scientific supervision:

Mgr. Martina Fialová
Laboratory Methods Department IKEM
Department of Clinical Immunology
Vídeňská 1958/9
140 21 Praha 4
e-mail: martina.fialova@ikem.cz

Mgr. Jan Martinek
Health Institute based in Ostrava
Department of Immunology and Allergology, CKL
Partyzánské nám. 7
728 92 Ostrava
e-mail: jan.martinek@zuova.cz

Supplements

As a supplement to this report, each participant who submitted the results gains:

Name	***Description***
Confirmation of attendance Result sheet	The conditions for issuing the relevant document specified in the EQA Plan must be met.

The supplements are identified by their name, EQA round identification and participant code and are intended for the needs of the participant.
If you reported the results in this round, you can find your individual evaluation (reports) in the **Cibule** application (https://www.eqa.cz/cibule). After login, select ***EQA Results - View*** in the menu and then click the ***Reports*** button for the particular round.

AIH2/26: Autoimmune Liver Diseases

Additional information

The final report, with the exception of the supplements, is public. Further information is freely available to the participants and other professionals at www.sekk.cz, in particular:

- The summary of the results of this round, including this final report.
- The document ***EQA Plan*** (contains information that applies both to this round and also the EQA in general).
- Explanation of the content of the particular supplements mentioned above.
- Contact to the EQA provider and the EQA coordinator and the list of all supervisors, including contacts.